Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trial Results - Progress in Cancer Care

These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.

The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.

  • Sorafenib Delays Progression of Metastatic Kidney Cancer
    (Posted: 02/07/2007, Updated: 06/08/2009) - The targeted drug sorafenib (Nevaxar®), which delays disease progression in patients with metastatic kidney cancer, may also improve survival of such patients, according to the May 18, 2009, Journal of Clinical Oncology.
  • Imatinib (Gleevec®) Reduces Cancer Recurrence in Patients with Surgically Removed GIST
    (Posted: 06/25/2007, Updated: 05/19/2009) - Patients with localized gastrointestinal stromal tumors (GIST) who took imatinib (Gleevec®) after surgical removal of the primary tumor were less likely to have a recurrence of their cancer, according to findings presented at the 2007 ASCO meeting in Chicago.
  • Maintenance Rituximab May Improve Survival in Follicular Lymphoma
    (Posted: 04/02/2009) - Follicular lymphoma patients who receive maintenance therapy with rituximab after their disease goes into remission may have better survival than those who do not receive such therapy, according to the February 18, 2009, issue of Journal of the National Cancer Institute.
  • Azacitidine Improves Survival in Myelodysplastic Syndromes
    (Posted: 03/26/2009) - The DNA methyltransferase inhibitor azacitidine (Vidaza®) improved overall survival in patients with higher-risk myelodysplastic syndromes, according to the March 2009 issue of Lancet Oncology.
  • Radiation Therapy Helps Prevent DCIS Recurrence After Breast-Conserving Surgery
    (Posted: 03/10/2009) - The addition of radiation therapy to breast-conserving surgery halves the risk of a tumor recurrence compared with surgery alone in women with noninvasive breast tumors, according to a pooled analysis of trial results published January 21, 2009, by the Cochrane Reviews.
< Previous  19 20 21 22 23 24 25 26 27 28 29 30 31 32  Next >